Price
CHART BY
Frequently asked questions
What is Ardelyx's market capitalization?
The market capitalization of Ardelyx is $1.64B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Ardelyx?
Ardelyx's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.237. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Ardelyx's stock?
Currently, 11 analysts cover Ardelyx's stock, with a consensus target price of $13.20. Analyst ratings provide insights into the stock's expected performance.
What is Ardelyx's revenue over the trailing twelve months?
Over the trailing twelve months, Ardelyx reported a revenue of $398.23M.
What is the EBITDA for Ardelyx?
Ardelyx's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$35.30M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Ardelyx?
Ardelyx has a free cash flow of -$55.35M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Ardelyx have, and what sector and industry does it belong to?
Ardelyx employs approximately 395 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Ardelyx's shares?
The free float of Ardelyx is 233.92M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.64B
- EPS (TTM)
- -$0.237
- Free Float
- 233.92M
- Revenue (TTM)
- $398.23M
- EBITDA (TTM)
- -$35.30M
- Free Cashflow (TTM)
- -$55.35M
Pricing
- 1D span
- $6.502$6.996
- 52W span
- $3.215$8.05
Analyst Ratings
The price target is $13.20 and the stock is covered by 11 analysts.
Buy
11
Hold
0
Sell
0
Information
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
- Employees
- 395
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- ARDX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet